Fantastic opp here This company has an incredibly valuable intellectual property portfolio and is essentially the only company now doing research on the relation between psilocybin and obesity, with a good chance of yielding results. They would effectively corner a market with a major lack of effective treatments if the current trial pans out (the obesity market). In addition, they have a top notch clincial team (feel free to look them - well published, well regarded scientists and academics).
Valuation only $30 million now where the avg R&D based name in the psychadelic space is $130 million with big names like MMED over a billion. Money will flow in here big time.
As for management, plenty of concern re: Penny White, but they replaced her with Robert Tessarolo, who has a good track record and led MMED during its early days. He left because the co-owners of the company wanted to take over after it went public and they did not see the need for an industry outsider when they were capable. The Intellectual property portfolio and clinical team is the real value here and it will send this higher as money flows generally into the sector. They also have a small product based business (mushroom coffees) to provide near-term revenue. If this is revalued to simply match its peers, this is a $1+ dollar stock